Susan G. Komen Blog

Stories about breast cancer that can inspire and inform

Blog  |  Newsroom

Spotlight on Clinical Trials

All Posts

3-Day

Advocacy

Cancer Updates

Care

Community

EmpowerED

Fundraising

Go Pink for the Cure

Know More

Komen Perspectives

MBC

News

Partnerships

Personal Stories

Real Talk

Research

ShareForCures

Spotlight on Clinical Trials

That's Hot: Menopause and Breast Cancer

You're Not Too Young, Bestie

A New Strategy to Reduce Hot Flashes Caused by Hormone Therapy for Hormone Receptor-Positive Breast Cancer 

Spotlight on Clinical Trials

Hormone receptor-positive (HR+) breast cancer is one of the most common types of breast cancer, making up about 70% to 80% of new diagnoses. In HR+ breast cancer, tumor cells have receptors for hormones such as estrogen (ER-positive) and/or progesterone (PR-positive), which can help fuel cancer growth. Because these tumor cells rely on hormones to grow, treatments that block or lower hormone […]

Shining a Spotlight on the Top Breast Cancer Clinical Trials Featured at ASCO 

Spotlight on Clinical Trials

Each year, the American Society of Clinical Oncology (ASCO) Annual Meeting offers new hope to the breast cancer community by showcasing the latest advances in breast cancer research and clinical care. Today, we are shining a spotlight on the top breast cancer clinical trials featured at ASCO. As researchers, health care professionals, advocates and patients from around the world gather in one place to network and discuss the latest breakthroughs, at the heart of these exciting advances are clinical trials.  […]

X-ray,Digital,Mammogram,Or,Mammography,Is,X-ray,Image,Of,The

Shining a Spotlight on Risk-Based Approaches to Breast Cancer Screening 

Spotlight on Clinical Trials

Mammography is the best tool available for finding breast cancer early. However, navigating the different recommendations from major health organizations, such as when to start receiving a mammogram and how often to go, can be confusing. These general guidelines often overlook the fact that every woman has unique, individual needs.  While many of these “one-size-fits-all” approaches have […]

Shining a Spotlight on a New Strategy to Prevent Recurrence in Estrogen Receptor-Positive/HER2-Negative Breast Cancer 

Spotlight on Clinical Trials

Estrogen receptor-positive (ER+)/HER2-negative (HER2-) breast cancer is one of the most common types of breast cancer, making up 70-80% of diagnoses. While the five-year relative survival rate for these patients is more than 95%, hormone receptor-positive breast cancers can recur (come back) more than 10 years after diagnosis, meaning there is an ongoing long-term risk of recurrence.   For many patients, this means living with constant stress and anxiety, even long after their treatments […]

Shining a Spotlight on a Proactive Approach to Prevent Recurrence in HR+/HER2-Breast Cancer 

Spotlight on Clinical Trials

Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-)  is the most common  breast cancer, making up more than 70% of all cases. Although HR+/HER2- breast cancer often has better outcomes than other types, it still presents long-term challenges, because it can recur (come back) several years after treatment.  In fact, according to a recent study, up to 30% of people with early-stage HR+/HER2- breast cancer may experience recurrence. This can happen even up to […]

Shining a Spotlight on Patient Advocate Involvement at SABCS

Spotlight on Clinical Trials

When patient advocates attend major conferences like the San Antonio Breast Cancer Symposium (SABCS), they help shape breast cancer clinical trials by sharing what patients really experience and need when it comes to research. They also help to translate complex science into clear, understandable information that helps patients make informed choices. That’s why patient advocate involvement is so important for improving clinical trials for patients.  In this installment of Spotlight on Clinical Trials, we explore just a few of the many ways that advocates help shape clinical trials and make a […]

Shining a Spotlight on More Personalized Treatment Strategies for Metastatic ER-Positive/HER2-Negative Breast Cancer 

Spotlight on Clinical Trials

Personalized treatments are transforming the landscape of care for people living with ER-positive (ER+)/HER2-negative (HER2-) metastatic breast cancer (MBC), by making therapy more effective and more tolerable. For those living with ER+/HER2- MBC, the standard first-line therapy usually includes hormone (endocrine) therapy paired with a CDK4/6 inhibitor. While these treatments work very well at first, […]

Shining a Spotlight on Promising Clinical Trials for Young Women 

Spotlight on Clinical Trials

In recent years, there has been a concerning rise in breast cancer diagnoses in young women (under age 50) in the United States. Although breast cancer is more commonly diagnosed in older women, more young women are being diagnosed, and some with aggressive tumors that require complex treatments. This is why clinical trials are especially […]

Shining a Spotlight on the Benefits of Complementary Therapies for Breast Cancer  

Spotlight on Clinical Trials

Complementary therapies are one of the most popular and rapidly growing options to help relieve some of the side effects of breast cancer treatment or the cancer itself. In fact, a recent national survey showed that 73% of breast cancer patients in the U.S. reported using at least one type of complementary therapy after their […]

Shining a Spotlight on More Effective Treatments for HER2+ MBC 

Spotlight on Clinical Trials

Despite important advances in breast cancer treatment, the disease can still find ways to outsmart even the best therapies. People living with HER2-positive metastatic breast cancer (HER2+ MBC) often respond well to treatments at first, with tumors shrinking or slowing down, but the effectiveness of these drugs doesn’t always last. Through the EmpowHER-303 clinical trial […]

A nurse walking through a 3D mammogram with a patient

Shining a Spotlight on the Benefits of 3D Mammograms 

Spotlight on Clinical Trials

Mammograms have been considered the gold standard for breast cancer screening for decades, but today’s mammogram screening recommendations don’t always offer a personalized approach. Today, most women may begin screenings at age 40, regardless of unique personal factors like ethnicity, family history or breast density. Researchers are exploring new ways to personalize breast cancer screening […]

1 2